Ignoring breast CAD findings need not breach standard of care

Article

Failure to act on computer-aided detection breast markings in areas judged to be benign or normal by experienced radiologists does not constitute a breach in the standard of care, according to a study in the March issue of Radiology. The researchers

Failure to act on computer-aided detection breast markings in areas judged to be benign or normal by experienced radiologists does not constitute a breach in the standard of care, according to a study in the March issue of Radiology.

The researchers recommend that radiologists follow standard interpretation procedures even when CAD marks a nonspecific finding.

"In the current legal climate, the appearance of a CAD mark at an area that eventually is shown to be malignant has caused much concern among radiologists. The standard of care for recalling a lesion for further investigation should not change based on such a CAD mark," said Dr. R. James Brenner, a lawyer and a clinical professor of radiology at the University of California, Los Angeles.

Brenner and colleagues at Stanford University and R2 Technology collected 493 pairs of mammogram studies. The pairs consisted of an initial negative screening mammogram and a follow-up screening mammogram indicating cancer. The average time between the two mammograms was 14.6 months.

Of the 493 pair, 169 cases (172 areas of cancer) had cancer indications so subtle that either none or only one or two of the five blinded radiologists participating in the study recommended a screening recall. They judged 80% of the 172 areas as having either a benign or normal appearance.

The investigators then examined the subtle findings with a CAD system. It marked 42% of the 172 cancer findings, or:
· 29% of the 82 findings not recalled by any of the radiologists,
· 49% of the 51 findings recalled by one radiologist
· 59% of the 39 findings recalled by two of the five radiologists

"If CAD identifies a significant abnormality that might not have been detected by a radiologist, then its value is straightforward. The degree to which this occurs is thus far unresolved," Brenner said.

A CAD mark does not necessarily reach a level of predictability that would necessitate a recall. But if a truly suspicious lesion is marked and not recalled, the interpreting radiologist would be required to provide a rationale for not recalling, he said.

"This would occur with or without a CAD mark. The same is true for lesions that are marked but are unlikely to represent cancer," he said. "The legal test for the law of negligence is not accuracy, but reasonableness."

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.